Oncology

News

Roche's Itovebi has become the first PI3K inhibitor to extend survival in HR-positive, HER2-negative breast cancer with a PIK3CA mutation.

News

There was good news for Johnson & Johnson at this week's ODAC meetings, but not for Roche, UroGen, and Pfizer.

News

BioNTech has said it will commit up to £1bn in investment in the UK over the next decade, in what has been described as a "template" for the sector.

News

Pfizer has joined the ranks of those developing cancer drugs that target PD-1 and VEGF, penning a $6bn licensing deal with China's 3SBio.

News

The revitalisation of GSK's blood cancer therapy Blenrep continues with a second approval, in Japan, as a second-line treatment for multiple myeloma.

News

Incyte has broken new ground in immuno-oncology, getting FDA approval for its Zynyz drug as a treatment for anal cancer